Keeping your car’s paint looking new has never been harder. Between road salt, UV exposure, automatic car washes, and ev ...

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...

The global biotechnology company announced minutes before the market closed on Tuesday that Mr McKenzie would be immediately replaced by Gordon Naylor, a current CSL director who has held a number of ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL’s interim chief executive Gordon Naylor has pleaded with angry investors for more time to return the global healthcare giant to its former glory, saying he will look at selling or scaling back non ...

Despite weaker-than-expected interim numbers, CSL maintains “ambitious” full-year guidance. But investors are sceptical Rhythm Biosciences enlists its first prescriber for its Colostat bowel cancer ...

The global biotech has lost $36bn in market value and axed its CEO, yet its interim boss insists CSL remains a ‘blue chip’ company. Battling lower vaccination rates in the US under the Trump ...

SYDNEY, Feb 11 (Reuters) - CSL Ltd (CSL.AX), opens new tab on Wednesday reported an 81% drop in first‑half profit, knocked by weaker blood plasma product and vaccine sales and one-off charges, a day ...

CSL has dumped chief executive Paul McKenzie after a brutal year for the global biotechnology giant, installing a former senior manager as interim boss following pressure from shareholders for a ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...